Class-Specific Considerations

Source: Cytiva

Here, BioMarin's Nimi Chhina explains the class-specific considerations for cell and gene therapy products that industry and regulators alike can collectively consider to drive policy development.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene